Safety of FOLFIRI + Durvalumab +/− Tremelimumab in Second Line of Patients with Advanced Gastric Cancer: A Safety Run-In from the Randomized Phase II Study DURIGAST PRODIGE 59

Efficacy of immune checkpoint inhibitors (ICI) as monotherapy in 2nd line treatment for gastric or gastro-oesophageal junction (GEJ) adenocarcinoma is low, with no evaluation of efficacy and safety of ICI combined with chemotherapy. The DURIGAST PRODIGE 59 study is a randomised, multicentre, phase I...

Descripción completa

Detalles Bibliográficos
Autores principales: Evrard, Camille, Aparicio, Thomas, Soularue, Emilie, Le Malicot, Karine, Desramé, Jérôme, Botsen, Damien, El Hajbi, Farid, Gonzalez, Daniel, Lepage, Come, Bouché, Olivier, Tougeron, David
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9138589/
https://www.ncbi.nlm.nih.gov/pubmed/35625947
http://dx.doi.org/10.3390/biomedicines10051211

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9138589/
https://www.ncbi.nlm.nih.gov/pubmed/35625947
http://dx.doi.org/10.3390/biomedicines10051211

Ejemplares similares